Axsome Reports 46% Revenue Growth in Q2 2026, Posts $51.3 Million Loss Amid Alzheimer's Expansion
The CNS-focused biotech delivered strong commercial momentum with flagship product AUVELITY growing 51% year-over-year, but losses widened on sales force expansion for new Alzheimer's indication.
Revenue Surge Driven by AUVELITY Growth
Axsome Therapeutics reported total net product revenue of $218.4 million for the second quarter of 2026, representing 46% year-over-year growth from $150.0 million in the comparable 2025 period (8-K filing, 2026-08-10). The New York-based CNS biopharmaceutical company's flagship product AUVELITY accounted for the majority of sales at $180.3 million, growing 51% year-over-year from $119.6 million.
The strong AUVELITY performance came on the heels of the company's June 2026 launch of the drug for treatment of agitation associated with dementia due to Alzheimer's disease, expanding beyond its original major depressive disorder indication. New-to-brand prescriptions among patients aged 65 and older increased 126% during the first eight weeks following the Alzheimer's launch compared to the same period in the prior quarter (8-K filing, 2026-08-10).
SUNOSI, the company's treatment for excessive daytime sleepiness, generated $35.8 million in net product revenue, up 20% year-over-year. SYMBRAVO, the migraine treatment launched in June 2025, posted $2.3 million in sales, representing 461% year-over-year growth from its nascent $0.4 million baseline.
Widening Losses on Commercial Investment
Despite robust revenue growth, Axsome's net loss widened to $51.3 million, or $0.99 per share, compared to a net loss of $48.0 million, or $0.97 per share, in the second quarter of 2025 (8-K filing, 2026-08-10). The increased losses were driven primarily by a significant ramp-up in selling, general, and administrative expenses, which jumped to $208.1 million from $130.3 million year-over-year.
The company attributed the SG&A increase to "commercialization activities for AUVELITY, including the sales force expansion and launch activities for the Alzheimer's disease agitation indication, and commercialization activities for SYMBRAVO" (8-K filing, 2026-08-10). The SYMBRAVO sales force expansion to approximately 150 representatives was described as "substantially complete."
Research and development expenses declined to $46.2 million from $49.5 million, primarily reflecting lower costs for AXS-05 and AXS-14 programs. The company reported cash and cash equivalents of $319.9 million at June 30, 2026, down slightly from $322.9 million at year-end 2025, with management stating that current cash is "sufficient to fund anticipated operations into cash flow positivity" (8-K filing, 2026-08-10).
Pipeline Progress and Regulatory Milestones
On the development front, Axsome announced that its New Drug Application for AXS-12 for the treatment of cataplexy in narcolepsy was accepted by the FDA with a PDUFA target action date of May 1, 2027 (8-K filing, 2026-08-10). The company also initiated two Phase 3 trials—FOCUS-2 and FOCUS-3—evaluating solriamfetol in children and adolescents with ADHD in June and July 2026.
MarginX data shows CEO Herriot Tabuteau recently executed options for 9,320 shares and sold 4,660 shares. The company's market capitalization stands at approximately $11 billion with shares last closing at $212.74.
Axsome expects topline results from its Phase 3 ENGAGE trial of solriamfetol in binge eating disorder in the fourth quarter of 2026, and plans to initiate a Phase 2/3 trial of AXS-05 in smoking cessation in the third quarter (8-K filing, 2026-08-10).
This article was generated by MarginX from the 8-K filing on 2026-08-10. It is not investment advice.